Shape the Future of ISPE Boston Educational Programs — We Want Your Input!

Posted by ISPE Boston
On June 20, 2025

The ISPE Boston Area Chapter is built on the foundation of collaboration, knowledge sharing, and professional growth. Every year, our educational programs are thoughtfully curated to reflect the evolving needs of our 1,600+ members—and now, it’s your turn to help guide what’s next. We’re inviting all members to take a quick moment to vote for […]

Lilly Buying Verve for $1.3 Billion

Posted by ISPE Boston
On June 20, 2025

In one of the largest acquisitions locally this year, Eli Lilly is buying Verve Therapeutics in a deal worth $1.3 billion. Boston-based Verve is a clinical-stage company developing genetic medicines for cardiovascular disease. The transaction is expected to close in Q3. Verve’s lead programs – VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers […]

Sage to be Acquired for $795 Million

Posted by ISPE Boston
On June 20, 2025

In more good news for local M&As, after rejecting an offer from Biogen in January, Sage Therapeutics has agreed to be acquired by Supernus Pharmaceuticals of Rockville, MD for $561 million, payable at closing, plus one non-tradable contingent value right (CVR) worth up to $234 million for a total of up to $795 million. The […]

Accelerating GMP Facilities: When Expertise Meets Energy

Posted by Eric Felz
On June 9, 2025

In the fast-paced world of pharmaceutical manufacturing, the race to bring life-saving treatments to market has never been more critical. Yet, the traditional approach to building Good Manufacturing Practice (GMP) facilities often feels like navigating a complex maze of regulatory requirements, technical challenges, and coordination hurdles. On May 15, 2025 a gathering at DPR Construction’s […]

Vigil Neuroscience to be Acquired by Sanofi

Posted by ISPE Boston
On June 5, 2025

Watertown-based Vigil Neuroscience has agreed to be acquired by drug giant Sanofi in a deal worth approximately $600 million. The transaction is expected to close in the third quarter of 2025. Vigil is a clinical-stage biotech focused on developing treatments for neurodegenerative diseases using microglia, the sentinel immune cells of the brain. Iluzanebart, Vigil’s lead […]

GSK Acquires Boston Pharmaceuticals’ Liver Drug for $1.2 Billion Plus

Posted by ISPE Boston
On June 5, 2025

GSK has agreed to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready, potential best-in-class, investigational drug for steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 billion upfront, with potential for additional success-based milestone payments totaling $800 million. Efimosfermin is an investigational, once-monthly subcutaneous injection of a long-acting variant of fibroblast […]

Chapter Member Anniversaries: June 2025

Posted by ISPE Boston
On June 4, 2025

Please congratulate the following members celebrating milestone anniversaries in June 2025. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Jason Carter, Alnylam Pharmaceuticals Robert G. Cole, Hart Design Group John F. Corcoran, CESCO Anthony V. Gopaul, STERIS Corporation Danny B. Haskell, NeoMatrix, Inc. Timothy J. Horgan, Alnylam […]

Welcome New Members May 2025

Posted by ISPE Boston
On June 4, 2025

We would like to introduce the Members who joined ISPE in May 2025, welcome them to the Chapter, and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

Forever Chemicals, Real Impacts: Insights from ISPE Boston’s PFAS Session

Posted by Howard Sneider
On May 19, 2025

The ISPE Boston Area Chapter was happy to host last month’s event: “PFAS: Understanding ‘Forever Chemicals’ and their potential impacts on pharmaceutical manufacturing”. The event was very informative, and the question-and-answer session postponed the end time by 45 minutes. Our speakers provided an informative session and left everyone in attendance with a greater understanding of […]

Bedford Site to be Redeveloped for Biomanufacturing

Posted by ISPE Boston
On May 8, 2025

Bain Capital Real Estate is teaming with Botanic Properties, a real estate investment and development firm focused on the biomanufacturing industry, to acquire 45 Crosby Drive in Bedford. The investment is being made by GenesisM, a specialized real estate platform dedicated to developing purpose-built biomanufacturing facilities. Financial terms of the purchase were not disclosed. The […]

Page 1 of 11812 3 ›»